A number of cannabis stocks are already trading on the NYSE, and reclassification could send prices shooting skyward. To get the right kind of investment advice and understand the market better, newbie investors in this industry will need a reliable source of information.The change would also make it easier for scientists to conduct federally approved research on marijuana, as it's very difficult for companies to research Schedule I drugs. This could uncover new use cases and open up new markets. This recla ...

President Trump is considering reclassifying marijuana as a less dangerous drug, after pot companies have poured millions of dollars into Trump’s political groups https://t.co/vyblxz9jZw ...

Trump says he may downgrade marijuana’s federal classification, a move that could ease sales and access for medical use https://t.co/vsBsQvCJlH ...

Policy & Regulation - The industry is closely monitoring President Trump's consideration of reclassifying marijuana as a less dangerous drug [1] Political Influence - Marijuana companies have invested millions of dollars into Trump's political groups [1]

Marijuana is bad for the brain. I published a study on a thousand marijuana users. Every area of their brain is lower in activity.And just today, a study came out in the Journal of the American Medical Association on,027 marijuana users. um it decreased activity in the hippocampus that affected their memory centers. If you're a teenager and you use marijuana in your 20s, you have a higher incidence of anxiety, depression, and suicide.This is not innocuous. And we've been advertised this load of crap which i ...

Company Overview - Altria is a consumer staples company primarily focused on cigarette production, which is distinct from other consumer staples companies that produce essential goods like food and toiletries [1][2] - The company has a high dividend yield of 7.4%, attracting dividend-focused investors [1] Market Dynamics - Cigarettes are not considered a necessity, but their addictive nature leads to consistent demand, even during economic downturns [2] - Historical data shows that during the pandemic in 2020, cigarette volumes only declined by 0.4%, but subsequent years have seen significant volume declines [3][5] Volume Decline - Altria's cigarette volumes have experienced a troubling trend: a 7.5% decline in 2021, 9.7% in 2022, 9.9% in 2023, and a projected 10.2% drop in 2024 [5] - The ongoing decline in cigarette volume poses a significant risk to the company's financial health and dividend sustainability [6] Pricing Strategy - The company has been offsetting volume declines through price increases, which has allowed it to maintain and increase its dividend [6] - However, there are concerns that continued price hikes may exacerbate volume declines in the long run [6] Strategic Challenges - Altria has attempted to diversify its business beyond cigarettes, investing in vaping and marijuana, but these efforts have not yielded successful outcomes [7] - The company's latest investment in NJOY is facing legal challenges, further complicating its growth strategy [7] Investment Considerations - Altria is struggling with its core cigarette business and has not effectively transitioned to new growth platforms, making it a risky investment for dividend-focused investors [8]